ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Therapeutic efficacy and oncological prognosis of ypTNM 0-I gastric cancer after neoadjuvant therapy: a multicenter propensity-score matched study in China.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNeoadjuvant therapy (NAT) effectively downstages locally advanced gastric cancer (LAGC), increasing the proportion of patients achieving ypTNM stage 0-I. However, it is still controversial whether the LAGC patients with better tumor regression (ypTNM stage 0-I) had similar prognosis compared with pTNM I early gastric cancer (EGC) patients or not. This study compared short- and long-term outcomes between ypTNM 0-I LAGC and EGC patients.
methodsA retrospective analysis of 1,193 patients with pTNM I EGC or ypTNM 0-I LAGC treated between January 2020 and November 2024 from three medical centers was conducted. Propensity score matching (PSM) at a 1:1 ratio balanced baseline characteristic. Short- and long-term outcomes were compared between groups.
resultsAfter PSM, baseline characteristics were comparable with no significant difference (P > 0.05). The ypTNM 0-I group had longer operative times, greater estimated blood loss, and extended postoperative hospital days compared with pTNM I group (P < 0.05), but no differences in complication rates, recurrence rates, 3-year overall survival (OS: 93.3% vs. 90.1%, P = 0.608) and recurrence-free survival (RFS: 90.3% vs. 87.7%, P = 0.301) between two groups. Multivariable Cox analysis identified nerve invasion as an independent risk factor for OS and RFS, while preoperative CEA ≥ 2.5 ng/mL was associated with poorer RFS (P < 0.05).
conclusionLAGC patients achieving ypTNM 0-I after NAT had comparable short- and long-term outcomes to pTNM I EGC patients. Nerve invasion and CEA levels ≥ 2.5 ng/mL were prognostic indicators for poorer survival.
Indexed as
Identifiers
41405741What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.